Evidence map›Paper›PMID 23589755›Full record

ArticlePloS one2013

Applying mathematical tools to accelerate vaccine development: modeling Shigella immune dynamics.

Courtney L Davis, Rezwanul Wahid, Franklin R Toapanta, Jakub K Simon, Marcelo B Sztein, Doron Levy

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Shigella-Controlled Human Infection Models: Current and Future Perspectives.Current topics in microbiology and immunology · 2024
    Review
  3. mSphere · 2021
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Courtney L DavisNatural Science Division, Pepperdine University, Malibu, California, United States of America. courtney.davis2@pepperdine.edu
Rezwanul Wahid
Franklin R Toapanta
Jakub K Simon
Marcelo B Sztein
Doron Levy
University of Maryland, Baltimore · USMichigan United · USPepperdine University · USUniversity of Maryland, College Park · US

Funding

Wild-type S. typhi Infection in Humans: Integrated Immunoprotective MechanismsU19AI082655 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SZTEIN, MARCELO B. · 2009 to 2018
$27.8M
Interplay Between Cancer and Immune Cells on Targeted TherapyR01CA130817 · NCI · STANFORD UNIVERSITY · PI LEE, PETER POON-HANG · 2008 to 2012
$2.1M
Immunological Correlates of Protection in ShigellosisK23AI065759 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SIMON, JAKUB K · 2005 to 2009
$809k
NCI NIH HHS R01 CA130817NCI NIH HHS R01CA130817NIAID NIH HHS K23AI06575NIAID NIH HHS K23 AI065759NIAID NIH HHS U19 AI082655
6 · The paper itself

Abstract

We establish a mathematical framework for studying immune interactions with Shigella, a bacteria that kills over one million people worldwide every year. The long-term goal of this novel approach is to inform Shigella vaccine design by elucidating which immune components and bacterial targets are crucial for establishing Shigella immunity. Our delay differential equation model focuses on antibody and B cell responses directed against antigens like lipopolysaccharide in Shigella's outer membrane. We find that antibody-based vaccines targeting only surface antigens cannot elicit sufficient immunity for protection. Additional boosting prior to infection would require a four-orders-of-magnitude increase in antibodies to sufficiently prevent epithelial invasion. However, boosting anti-LPS B memory can confer protection, which suggests these cells may correlate with immunity. We see that IgA antibodies are slightly more effective per molecule than IgG, but more total IgA is required due to spatial functionality. An extension of the model reveals that targeting both LPS and epithelial entry proteins is a promising avenue to advance vaccine development. This paper underscores the importance of multifaceted immune targeting in creating an effective Shigella vaccine. It introduces mathematical models to the Shigella vaccine development effort and lays a foundation for joint theoretical/experimental/clinical approaches to Shigella vaccine design.

Indexed as

Models, ImmunologicalAlgorithmsAntibodies, BacterialComputer SimulationDysentery, BacillaryHost-Pathogen InteractionsHumansIntestinal MucosaShigellaShigella VaccinesAntibodies, BacterialShigella Vaccines

Identifiers

PMID23589755
PMCPMC3614931
OpenAlexW2052915368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.